Last year, the UK Department of Health & Social Care issued a statement emphasizing their continued support for the acceptance of batch testing and certification by a Qualified Person (QP) performed in the EU. This statement came after a public consultation seeking opinions on four potential options for a batch testing policy in the UK
The European Medicines Agency (EMA) has launched a pilot project to assess the benefits of analyzing raw data from clinical trials by regulatory authorities when evaluating marketing authorization applications (MAAs) for new medicines, as well as post-authorization applications. Raw data constitutes individual patient data from clinical studies in electronic structured format that is directly accessible
Following a 1-month feedback period on the draft published in June last year the European Commission (EC) finally adopted on 6 September 2022 the revised Annex VI to Regulation (EU) No 536/2014 (Clinical Trials Regulation, CTR) as regards labelling requirements for IMPs. The Regulation will enter into force on the twentieth day following its publication in the
Our CEO Ann McGee will be speaking at the Pharma and Brexit Conference - hosted by PDA Ireland and PDA United Kingdom. The event will focus on the impact, challenges and solutions for the pharmaceutical industry. Register now on Eventbrite: https://lnkd.in/eVxTutkC Date - September 23rd, 2022 Venue - Crowne Plaza Hotel, Dublin Airport Time - 8:00 a.m. -
We are very excited to announce the appointment of Pierre-HenriBaviera as the new CEO for Mias Pharma Limited. As an experienced CEO, Pierre brings significant senior international leadership capabilities in Professional Services and Technology companies. He will be focused on the next phase of growth for MIAS's people and customers in line with our
MIAS Pharma will be attending the following events in the coming months: 35th Annual Congress of the European Association of Nuclear Medicine (EANM), Barcelona, 15th - 19th of October 2022. The EANM’s vision is to optimise and advance science and education in nuclear medicine for the benefit of public health and humanity within the
MIAS has continued exceptional growth and development over 2021. We'd like to thank our Team, Customers and Suppliers for contributing to the continued success of MIAS. We would like to wish you all a very Merry Christmas and we look forward to what will come in 2022. Our offices will close on Friday 24th
We would like to welcome Ciara Kearney, Lisa Evans, Sherry A Calimlim and Olivia McEvoy to the MIAS Pharma Team. They are a very welcome addition to the team and we look forward to a long and fruitful career with MIAS.